Oculis Appoints Mark Kupersmith, MD, and Sebastian Wolf, MD, Ph.D., as Chief Medical Advisors

ZUG, Switzerland—Oculis Holding AG, (Nasdaq: OCS; XICE: OCS) a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases, has announced the appointments of Mark Kupersmith, MD, as chief medical advisor, neuro-ophthalmology, and Sebastian Wolf, MD, Ph.D., as chief medical advisor, ophthalmology, effective immediately. In making the announcement, the company lauded Dr. Kupersmith’s scientific expertise in both ophthalmology and neurology as well as significant experience as a researcher and clinician, which the company said “will be critical to Oculis’ expansion into neuro-ophthalmology and beyond.”